The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma

ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge, and the aggressive basal‐like/mesenchymal subtype is particularly refractory to chemotherapy, underscoring the need for novel therapies. Leveraging genetic screens, we identified protein phosphatase 2A (PP2A) catalytic...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Janine Murr, Carolin Schneider, Ningjun Duan, Hazal Köse, Anantharamanan Rajamani, Xueyang He, Jonas Buchloh, Christian Hintze, Atharva Naik, Daniel Goeke, Nicole Rjasanow, Lukas Krauß, Alexandra Nguyen, Sebastian A. Widholz, Christian Schneeweis, Riccardo Trozzo, Felix Orben, Sebastian Mueller, Rupert Öllinger, Juan J Montero, Michael Dudek, Percy Knolle, Bo Kong, Volker Ellenrieder, Constanza Tapia Contreras, Elisabeth Hessmann, Marian Grade, Michael Ghadimi, Christian J. Braun, Roland Rad, Maximillian Reichert, Ulrich Keller, Roland M. Schmid, Paul L. Boutz, Dieter Saur, Matthias Wirth, Oliver H. Krämer, Günter Schneider
Format:	Artigo
Sprog:	Inglês
Udgivet:	Wiley 2026-06-01
Serier:	MedComm
Fag:	cyclin‐dependent kinase 9 mesenchymal pancreatic cancer protein phosphatase 2A transcription
Online adgang:	https://doi.org/10.1002/mco2.70794
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!